Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along ...